SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

The market is focused on the expected interest rate decision, with community chatter split between anticipating a rally or a "sell the news" reaction. Many traders believe a 0.25% rate cut is already priced in, while others are closely watching Fed Chair Powell's commentary for further cues on the economic outlook and future monetary policy. Community members also discuss potential sector rotations and the impact of rate decisions on various asset classes.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as the market anticipates the Fed's rate decision, with widespread expectation of a 25 bps cut. Community members are closely watching Powell's tone and forward guidance, as well as potential sector rotations and the impact on small caps. Uncertainty surrounding inflation and labor market conditions adds to the speculation around the technology-heavy index.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor (OPEN) is trending amid discussions about the Federal Reserve's rate cut decision and its potential impact on the housing market; the community is debating whether the rate cut will stimulate growth or if it was already priced in. Some traders are pointing to the company's expansion plans as a catalyst, while others speculate about potential announcements from the CEO. Overall, the conversation revolves around the tug-of-war between bullish hopes for real estate and bearish concerns about market reactions.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending as investors anticipate the Fed's rate cut decision and its potential impact on crypto markets, with some expecting a bullish outcome and others bracing for a "sell the news" event. Community members are actively discussing potential price targets, the influence of rate cuts, and the performance of altcoins relative to Bitcoin. Broader discussions encompass Bitcoin's role as a store of value and its correlation with traditional markets.

BlackRock Institutional Trust Company N.A. - iShares Russell 2000 ETF

iShares Russell 2000 ETF

IWM is trending due to anticipation surrounding a potential Federal Reserve rate cut, with the market pricing in possible easing. Community discussions revolve around the impact of rate cuts on small-cap stocks and whether the expected news is already priced in, potentially leading to a "sell the news" event. Traders are closely watching for signals about the Fed's future policy and its effects on various sectors, especially small caps.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai ($BBAI) is trending due to a combination of factors, including increased institutional buying from Goldman Sachs and a congresswoman's disclosed investment. The community is actively discussing the potential for a short squeeze and the impact of upcoming Fed decisions on the stock's momentum, as well as potential government contracts. Overall sentiment appears bullish, with many anticipating further gains and a breakout above key resistance levels.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Conversations around Webull Corp (BULL) are focused on potential dilution and reverse splits, with some traders expressing frustration over the stock's performance despite broader market gains and upcoming rate cut decisions. Community sentiment is mixed, with some calling it a "garbage" stock and others anticipating a potential short squeeze or a move to higher price targets, especially with the potential of rate cuts. Some are drawing comparisons to similar companies, mentioning potential catalysts to be a breakout stock like competitors $HOOD and $SOFI.

SSgA Active Trust - SPDR Dow Jones Industrial Average ETF

DIA is trending due to speculation around potential Fed rate cuts following weaker-than-expected jobs data, with the community debating whether this is a bull trap or a genuine signal for further market gains. Community members are closely watching upcoming inflation reports for further clues, while some express concern about the reliability of economic data. Debate continues about whether to "buy the dip" or prepare for a significant correction.

BlackRock Institutional Trust Company N.A. - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is trending as traders anticipate potential Fed rate cuts following recent economic data and await upcoming CPI and PPI reports, leading to discussions about recession risks and the bond market's next move. Community perspectives range from expectations of a bond rally to concerns about stagflation, with some highlighting the influence of tariffs and potential central bank actions. The conversation also involves analysis of technical indicators and potential trading strategies.

TOSHI

TOSHI.X is trending amid community excitement around new exchange listings, particularly in South Korea, and speculation about potential future listings on major platforms like Binance. Talk of a recent partnership with Coinbase is circulating, as well as anticipation surrounding potential interest rate cuts and their impact on the crypto market. The community is also actively discussing the coin's technical outlook and potential for significant gains.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Eli Lilly and Company (LLY) stated on Wednesday that its oral weight-loss drug was found to be superior to its rival Novo Nordisk’s (NVO) oral Semaglutide in a head-to-head late-stage trial.The study evaluated the safety and efficacy of Lilly’s Orforglipron in 1,698 adults with type 2 diabetes as compared to oral Semaglutide. At 52 weeks, Orforglipron met the primary as well as secondary endpoints across each dose comparison vs. oral Semaglutide, delivering greater improvements in average blood sugar levels and weight, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-superior-oral-semaglutide-head">said</a>.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/LLY">LLY stock</a> stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.Kenneth Custer, executive vice president and president of Lilly Cardiometabolic Health, said that in the trial, Orforglipron outperformed both doses of oral Semaglutide in reducing blood glucose levels. “At the highest dose, Orforglipron helped nearly three times as many participants reach near-normal blood sugar versus the highest dose of oral Semaglutide,” he said, while adding that head-to-head trials are a “gold standard for comparing potential treatments."The trial compared 12 mg and 36 mg of Orforglipron with 7 mg and 14 mg of oral Semaglutide. Orforglipron lowered blood glucose levels by as much as 2.2% compared to 1.4% with the highest dose of oral Semaglutide at 52 weeks. Notably, 37.1% of participants taking the highest dose of Orforglipron achieved a blood glucose level lower than 5.7% compared to 12.5% taking the highest dose of oral Semaglutide, Lilly said.Furthermore, participants taking Lilly’s drug achieved as much as a 9.2% reduction in weight from baseline, compared to 5.3% with oral Semaglutide, the company said. Orforglipron also showed clinically meaningful improvements across key cardiovascular risk factors, it added.Treatment discontinuation rates due to adverse events, however, were higher in the Orforglipron population, though the study was not powered to compare the safety and tolerability of Orforglipron and oral Semaglutide.Treatment discontinuation rates due to adverse events were 8.7% for 12 mg Orforglipron and 9.7% for 36 mg Orforglipron, as compared to 4.5% for 7 mg oral Semaglutide and 4.9% for 14 mg oral Semaglutide, Lilly said.The company expects to submit applications for Orforglipron for the treatment of type 2 diabetes to global regulatory agencies in 2026. Oral Semaglutide, meanwhile, is already approved for the treatment of type 2 diabetes under the name Rybelsus.LLY stock is down by 15% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/astrazeneca-says-asthma-drug-failed-trial-in-smokers-disease/chDGnwkRd64">AstraZeneca Says Asthma Drug Failed Trial In Smoker’s Disease</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A sign with the company logo sits outside of the headquarters campus of Eli Lilly and Company on March 17, 2024 in Indianapolis, Indiana. (Photo by Scott Olson/Getty Images)

Eli Lilly Says Its Obesity Pill Topped Novo Nordisk’s Oral Drug In Late-Stage Diabetes Trial

At 52 weeks, Orforglipron met the primary and all key secondary endpoints across each dose comparison as compared to oral Semaglutide, delivering greater improvements in average blood sugar levels and weight, the company said.

Equity

At 52 weeks, Orforglipron met the primary and all key secondary endpoints across each dose comparison as compared to oral Semaglutide, delivering greater improvements in average blood sugar levels and weight, the company said.


AMGN vs. VKTX: Which Biotech Stock Is the Better Obesity Play?

Amgen's MariTide and Viking's VK2735 show promise in obesity, but pipeline strength and performance set the two biotech players apart.

The U.S. Food and Drug Administration has sent a letter to Novo Nordisk (NVO) CEO Maziar Mike Doustdar regarding the company’s promotional communication featuring Oprah Winfrey, alleging that the video is false or misleading.The video originally appeared on ABC as a Primetime Oprah Special on March 18, 2024. It also subsequently appeared on Hulu. The video is a 42-minute special program hosted by Oprah Winfrey, featuring patient testimonials from individuals who struggle with obesity and excessive weight, including those who have used Novo’s Wegovy, Ozempic, or Victoza.The FDA <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/novo-nordisk-inc-716495-09092025">alleged</a> in a letter dated September 9 that the video misbranded Novo’s Wegovy, Ozempic, and Victoza, making its distribution violative. The video was also not submitted at the time of initial dissemination or publication as required by law, the agency said.“These violations are concerning from a public health perspective because the promotional communication creates a misleading impression regarding the safety of Wegovy, Ozempic, and Victoza, which are drugs with multiple serious, potentially life-threatening risks,” the agency said.The FDA also noted that obesity and type 2 diabetes are significant public health concerns in the U.S., and consumers who seek medical treatment for these conditions should receive truthful and nonmisleading information regarding the serious risks associated with the use of the drugs. While Novo’s Wegovy is used for weight management, its Ozempic and Victoza are used to treat type 2 diabetes.The FDA said that several advisory comments dated as long back as 2010 addressed draft promotional communications for Victoza with certain similarities to the aforementioned video. The agency expressed concerns that <a href="https://stocktwits.com/symbol/NVO">Novo</a> is promoting the three drugs in a manner that fails to present the serious risks of these drug products in a truthful and nonmisleading manner, despite the FDA’s prior comments.While the video includes numerous representations of the benefits of Wegovy, Ozempic, and Victoza made by representatives of Novo Nordisk, it omits important risk information or minimizes the risks associated with these drug products, the FDA said. Only four minutes in total were devoted to the important risks associated with GLP-1 drugs, such as Wegovy, the FDA said.The video also omits reference to how the drugs are contraindicated in patients with a personal or family history of Medullary Thyroid Cancer or in patients with Multiple Endocrine Neoplasia syndrome type 2, it added. The omissions are exacerbated by statements from Amanda Velazquez, a paid consultant of Novo, made on the video, the FDA said.NVO stock is down by 33% this year and by 58% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/hims-and-hers-stock-tumbles-7-percent-after-fda-letter/chwyNFWRdzV">Hims &amp; Hers Stock Draws Investor Attention After Tumbling 7% – Here’s What Happened</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ozempic manufactured by Novo Nordisk packaging is seen in this illustration photo taken in a pharmacy in Krakow, Poland on December 7, 2023. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

US FDA Alleges Novo Nordisk’s Video On Weight-loss Drugs Featuring Oprah Winfrey Is ‘False Or Misleading’ 

The FDA alleged in a letter dated September 9 that the video misbranded Novo’s Wegovy, Ozempic, and Victoza, making its distribution violative. 

Is ABBV Stock a Buy, Hold, or Sell After Its Almost 23% Rise YTD?

AbbVie surges 22.5% YTD as new drugs Skyrizi and Rinvoq drive growth, offsetting Humira losses and fueling long-term momentum.

Novo Nordisk (NVO) announced on Tuesday that its new obesity treatment, Cagrilintide, reduced body weight by 11.8% after 68 weeks in a late-stage study.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916427">reported</a> an average weight loss of 12.5 kg, compared to 2.5 kg with the placebo, in the trial evaluating the efficacy and safety of once-weekly Cagrilintide 2.4 mg monotherapy, plus lifestyle intervention, for adults with obesity or overweight and a weight-related comorbidity without diabetes. The above levels of weight reduction were observed in participants who adhered to the treatment. Regardless of adherence, average weight loss with Cagrilintide was 11.5% compared to 3.0% with placebo after 68 weeks.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NVO">NVO stock</a> stayed within the ‘bearish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels. Shares of the company traded over 2% higher at the time of writing.<figure class="image"><img style="aspect-ratio:575/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_16_at_9_59_21_AM_png_2efadb4b5b.webp" alt="NVO's Sentiment Meter and Message Volume as of 9:59 a.m. ET on Sept. 16, 2025 | Source: Stocktwits" width="575" height="60"><figcaption>NVO's Sentiment Meter and Message Volume as of 9:59 a.m. ET on Sept. 16, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed disappointment that the stock rallied only 2-3% on good news.<stembedurl>https://stocktwits.com/King990/message/628811943</stembedurl>Cagrilintide works differently from currently approved GLP-1-based treatments for weight loss, including Novo’s Wegovy and Eli Lilly’s Zepbound. The new drug mimics the naturally occurring hormone amylin that helps control blood glucose levels and appetite by slowing gastric emptying, reducing glucagon secretion, and promoting satiety.The company also stated that approximately one in three participants receiving Cagrilintide achieved 15% or more weight loss, compared to approximately one in 20 participants receiving a placebo, when patients adhered to the treatment.Novo stated that the drug was well-tolerated, while adding that the most common side effects were gastrointestinal, including nausea, vomiting, diarrhoea, and constipation. These side effects were mainly temporary and mild to moderate, and 1% of participants discontinued the study due to nausea, compared to 0.1% of participants who received a placebo.“We’re excited that these data, the first phase 3 data of a next-generation amylin therapy, show promise, and we look forward to further investigating cagrilintide’s potential in the dedicated phase 3 RENEW programme,” said Martin Holst Lange, chief scientific officer and executive vice president of Research and Development at Novo Nordisk.Another late-stage programme investigating the efficacy and safety of Cagrilintide in people with obesity or overweight is due to start in the fourth quarter of this year.Separately, Bloomberg <a target="_blank" rel="noopener noreferrer nofollow" href="https://bloomberg.com/news/articles/2025-09-16/novo-plans-to-seek-us-approval-for-its-high-dose-obesity-shot?sref&amp;#61;8QBk7toa">reported</a> on Tuesday that Novo plans to seek U.S. regulatory approval for a high-dose version of Wegovy. Though the drugmaker hasn’t yet formally announced its U.S. plans, it intends to file for the U.S. Food and Drug Administration approval, said Lange at the European Association for the Study of Diabetes conference in Vienna, according to the report.NVO stock is down 34% this year and by about 58% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/us-regulator-opens-probe-into-174000-plus-tesla-model-y-vehicles/chwyiNgRdz5">US Regulator Opens Probe Into 174,000-Plus Tesla Model Y Vehicles – Check Out Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Novo Nordisk logo is displayed on a smartphone with stock market percentages in the background. (Photo Illustration by Omar Marques/SOPA Images/LightRocket via Getty Images)

Novo Nordisk Says New Obesity Treatment Achieved 11.8% Body Weight Reduction In Late-Stage Study

The company reported an average weight loss of 12.5 kg, compared to 2.5 kg with the placebo, in a trial evaluating the efficacy and safety of once-weekly Cagrilintide 2.4 mg monotherapy. 

Will Rybelsus' Updated EU Label Propel Fresh Growth Potential for NVO?

Novo Nordisk gains EU approval for adding the cardiovascular indication to Rybelsus' label, strengthening its edge in the competitive diabetes market.

Lilly Moves Past 50-Day SMA: Should You Consider Buying the Stock Now?

Eli Lilly shares move past the 50-day SMA as weight-loss drug data, rising sales and pipeline momentum fuel optimism.

Eli Lilly (LLY) and Novo Nordisk (NVO) are reportedly expected to launch oral obesity pills by next year once they get regulatory approval in the U.S.According to a CNBC report, which cited an interview with Lilly’s Chief Scientific Officer, Dan Skovronsky, the company anticipates receiving results in the next few months from a head-to-head trial between its oral drug, Orforglipron, and Novo Nordisk’s oral Semaglutide. Daily pills would likely bring GLP-1s to more people, the report stated.&nbsp;The report noted that the primary aim of the study is to assess the effectiveness of the pills in lowering blood sugar levels in individuals with Type 2 diabetes, while also monitoring their impact on weight loss.“We wouldn’t have undertaken this head-to-head phase three randomized control trial unless we had a lot of confidence that orforglipron would fare well in comparison to oral semaglutide,” Skovronsky told CNBC.Retail sentiment on <a href="https://stocktwits.com/symbol/LLY">Eli Lilly</a> remained unchanged in the ‘neutral’ territory, with message volumes at ‘low’ levels, according to Stocktwits data.The report said that Skovronsky noted the results across trials, which did not directly compare the two drugs, should not be made, given Novo’s pill appears more effective with fewer discontinuations.&nbsp;Meanwhile, Novo’s Chief Scientific Officer, Martin Holst Lange, told CNBC in another interview that the data speaks for itself.Retail sentiment on <a href="https://stocktwits.com/symbol/NVO">Novo</a> remained in the ‘bearish’ territory, with chatter at ‘low’ levels, according to data from Stocktwits.The report explained that Novo’s upcoming obesity pill is a tablet form of its weekly injection, Wegovy. In contrast, Lilly’s pill, Orforglipron, is a completely new drug and different from its injectable treatment, Zepbound. According to Skovronsky, Zepbound remains the benchmark for effectiveness, helping patients lose over 20% of their body weight.The CNBC report noted that neither Novo’s pill nor Lilly’s oral drug is as effective as Zepbound. It added that Orforglipron&nbsp;has achieved around 12% weight loss at its highest dose, while oral Semaglutide&nbsp;has reached about 17%, prompting uncertainty over how many patients will choose a pill if it delivers less weight loss than injectable options.Skovronsky told CNBC that pills could eventually become the primary way that obesity would be treated, and that oral drugs could have a larger market share than shots.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/rh-stock-sees-slew-price-target-cuts-from-wall-street-as-trump-tariffs-bite/chw8MrGRdDN">RH Stock Sees Slew Of Downgrades, Price Target Cuts From Wall Street As Trump Tariffs Bite</a>

While Lilly’s broader portfolio spans diabetes, cancer, and neuroscience treatments, investors remain largely focused on Mounjaro and Zepbound. 

Eli Lilly, Novo Nordisk Preparing To Introduce Obesity Pills Next Year In The US: Report

According to a CNBC report, which cited an interview with Lilly’s Chief Scientific Officer, Dan Skovronsky, the company expects trial results within months from a direct comparison between its oral drug Orforglipron and Novo Nordisk’s Semaglutide.

According to a CNBC report, which cited an interview with Lilly’s Chief Scientific Officer, Dan Skovronsky, the company anticipates receiving results in the next few months from a head-to-head trial between its oral drug, Orforglipron, and Novo Nordisk’s oral Semaglutide. 

Where Does VKTX Stock Stand After the Obesity Pill Setback?

Viking Therapeutics faces pressure after mixed oral obesity pill trial results, raising safety concerns but still meeting key study goals.

Prothena Down 40% Year to Date: What Lies Ahead for the Stock? 

Prothena stock tumbles 40% year to date due to pipeline setbacks, though its partnered programs with Roche and Novo Nordisk still show potential.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Just the one

Three

Four

The Fed just cut rates. How many cuts do you expect in all of 2025? 
 
*Powered by Polymarket

NVO
Novo Nordisk A/S

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NVO News

NVO Novo Nordisk A/S